P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL

• Tycel Phillips,
• Michael Wang,
• Tadeusz Robak,
• David Gallinson,
• Don Stevens,
• Krish Patel,
• Safaa Ramadan,
• Chuan-Chaun Wun,
• Wojciech Jurczak,
• Stephen D. Smith

Affiliations

Tycel Phillips

1 University of Michigan Comprehensive Cancer Center, Ann Arbor, United States

Michael Wang

2 MD Anderson Cancer Center, University of Texas, Houston, United States

Tadeusz Robak

3 Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland

David Gallinson

4 Summit Medical Group, Florham Park, United States

Don Stevens

5 Norton Cancer Institute, Louisville, United States

Krish Patel

6 Swedish Medical Center, Seattle, United States

Safaa Ramadan

7 AstraZeneca, Cambridge, United Kingdom

Chuan-Chaun Wun

8 AstraZeneca, South San Francisco, United States

Wojciech Jurczak

9 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

Stephen D. Smith

10 Fred Hutchinson Cancer Center, Seattle, United States